Aligos Therapeutics, Inc. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 14 rows in 2026. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2026-06-25: Reporting owner Preston Heather; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-06-25: Reporting owner Chavez Margarita; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-06-25: Reporting owner Martell Bridget A; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2026-06-25: Reporting owner Scopa James Paul; Form 4; Security Stock Option (Right to Buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
ALGS insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-25 | Preston Heather Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,860 5,860 owned after | $5.50 exercise price | $5.50 | 2026-06-29 |
| 2026-06-25 | Chavez Margarita Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,860 5,860 owned after | $5.50 exercise price | $5.50 | 2026-06-29 |
| 2026-06-25 | Martell Bridget A Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,860 5,860 owned after | $5.50 exercise price | $5.50 | 2026-06-29 |
| 2026-06-25 | Scopa James Paul Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,860 5,860 owned after | $5.50 exercise price | $5.50 | 2026-06-29 |
| 2026-06-25 | Nuechterlein Carole Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,860 5,860 owned after | $5.50 exercise price | $5.50 | 2026-06-29 |
| 2026-06-25 | Hirth Peter Director | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +5,860 5,860 owned after | $5.50 exercise price | $5.50 | 2026-06-29 |
| 2026-03-09 | Symons Julian A. Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +23,310 23,310 owned after | $7.03 exercise price | $7.03 | 2026-03-11 |
| 2026-03-09 | Aneja Nikhil Officer (Principal Accounting Officer) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,450 9,450 owned after | $7.03 exercise price | $7.03 | 2026-03-11 |
| 2026-03-09 | Calhoun Lesley Ann Officer (See Remarks) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +37,485 37,485 owned after | $7.03 exercise price | $7.03 | 2026-03-11 |
| 2026-03-09 | BLATT LAWRENCE Director, Officer (President and CEO) | 4 | Stock Option (Right to Buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +105,840 105,840 owned after | $7.03 exercise price | $7.03 | 2026-03-11 |
| 2026-02-19 holding as of filing | Aneja Nikhil Officer (Principal Accounting Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $16.00 exercise price | 2026-02-19 | ||
| 2026-02-19 holding as of filing | Aneja Nikhil Officer (Principal Accounting Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $11.74 exercise price | 2026-02-19 | ||
| 2026-02-19 holding as of filing | Aneja Nikhil Officer (Principal Accounting Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $16.87 exercise price | 2026-02-19 | ||
| 2026-02-19 holding as of filing | Aneja Nikhil Officer (Principal Accounting Officer) | 3 | Stock Option (Right to Buy) Derivative · Direct | Holding | $8.68 exercise price | 2026-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |